The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Authors :: Jens, Bauer
Natalie, Köhler
Yacine, Maringer
Philip, Bucher
Tatjana, Bilich
Melissa, Zwick
Severin, Dicks
Annika, Nelde
Marissa, Dubbelaar
Jonas, Scheid
Marcel, Wacker
Jonas S, Heitmann
Sarah, Schroeder
Jonas, Rieth
Monika, Denk
Marion, Richter
Reinhild, Klein
Irina, Bonzheim
Julia, Luibrand
Ursula, Holzer
Martin, Ebinger
Ines B, Brecht
Michael, Bitzer
Melanie, Boerries
Judith, Feucht
Helmut R, Salih
Hans-Georg, Rammensee
Stephan, Hailfinger
Juliane S, Walz
Source :: Nature communications. 13(1)
Publication Year :: 2022
Abstract: The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA class II ligands induce multifunctional cytotoxic CD8

Subjects :: Gene Expression Regulation, Neoplastic
Cyclic AMP-Dependent Protein Kinase Catalytic Subunits
Carcinoma, Hepatocellular
Oncogene Proteins, Fusion
Liver Neoplasms
Humans
Immunotherapy
Neoplasm Recurrence, Local
HSP40 Heat-Shock Proteins
Peptides

Tools